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The induction of host antimicrobial molecules follow-
ing binding of pathogen components to pattern recogni-
tion receptors such as CD14 and the Toll-like receptors
(TLRs) is a key feature of innate immunity. The human
airway epithelium is an important environmental inter-
face, but LPS recognition pathways have not been de-
termined. We hypothesized that LPS would trigger
b2defensin (hBD2) mRNA in human tracheobronchial
epithelial (hTBE) cells through a CD14-dependent mech-
anism, ultimately activating NF-kB. An average 3-fold
increase in hBD2 mRNA occurs 24 h after LPS challenge
of hTBE cells. For the first time, we demonstrate the
presence of CD14 mRNA and cell surface protein in
hTBE cells and show that CD14 neutralization abolishes
LPS induction of hBD2 mRNA. Furthermore, we demon-
strate TLR mRNA in hTBE cells and NF-kB activation
following LPS. Thus, LPS induction of hBD2 in hTBE
cells requires CD14, which may complex with a TLR to
ultimately activate NF-kB.
The innate immune response comprises the first line of host
defense against pathogenic microorganisms. Many protective
elements including nitric oxide, peptides/proteins, and whole
cells such as phagocytes and natural killer cells have been
conserved during evolution. Studies in Drosophila illustrate
the primary importance of pathogen recognition and induction
of antimicrobial molecules. Toll mutations preventing antifun-
gal peptide induction render mutant flies susceptible to fungal
infection (1). Signaling through Drosophila Toll results in ac-
tivation of members of the NF-kB family of transcription fac-
tors and expression of antimicrobial factors (2). Pathways for
pattern recognition and signaling have been identified in mam-
mals where Toll-like receptors (TLRs)1 (3, 4) and NF-kB pro-
vide functions similar to Drosophila Toll and dorsal or Dif,
respectively (5, 6).
Innate immunity is induced when loosely defined recognition
elements of microbes bind to pattern recognition receptors
present on both phagocytic and epithelial cells (7). These re-
ceptors include the mannose receptor (8), the GPI-linked LPS
co-receptor CD14 (9) and the TLRs (3). In human macrophages,
TLR2 acts in concert with CD14 to bind LPS and initiate a
signaling cascade (10, 11). The mouse TLR4 homologue is an
important determinant of LPS responsiveness (12). In general,
activation of pattern recognition receptors induces host defense
gene products.
As a primary interface between pathogens and the environ-
ment, epithelial cells lining the mammalian airways are a
crucial site for the innate immune response. It has been pro-
posed that dysfunction of innate immunity may result in re-
current airway infections as seen in cystic fibrosis (13). The
bovine b-defensin tracheal antimicrobial peptide (TAP) serves
as a paradigm for induction of innate immunity in the airway
(14). The TAP gene is expressed in the ciliated airway epithe-
lium (15) and is induced following experimental bacterial in-
fection (14). In vitro incubation of bovine tracheal epithelial
cells with LPS increases TAP mRNA levels via a CD14-medi-
ated response (14), culminating in NF-kB activation and tran-
scriptional up-regulation of the TAP gene (16). Thus, in the
bovine airway epithelium antimicrobial peptides are induced
through a well defined recognition and activation pathway that
helps prevent microbial colonization.
Two b-defensins are present in human epithelia. Human
b-defensin-1 (hBD1) (17) is highly expressed in urogenital tis-
sues (18), and to a lesser extent in airway and other epithelia,
entirely in a constitutive manner (19). Human b-defensin-2
(hBD2) was initially found in psoriatic skin and is present in
cultured keratinocytes in response to bacteria (20). The hBD2
gene is similar to TAP and includes three NF-kB consensus
sequences upstream from the transcriptional initiation site
(21). The mRNA for hBD2 is present in human lung (22) and is
up-regulated in chronic inflammation and by the proinflamma-
tory mediator IL-1b (23). Thus, hBD2 is a host defense mole-
cule whose production is induced in response to infection and
inflammation. Purified hBD2 peptide acts synergistically with
other antibacterial components of the airway surface fluid,
including lysozyme and lactoferrin (22), suggesting a role in
maintaining a pathogen-free environment.
As an innate immune response tissue, the human airway
must recognize pathogen-associated molecular patterns such
as LPS via cell surface receptors. Surprisingly, neither CD14
nor TLRs have been documented in human tracheobronchial
epithelial (hTBE) cells. We hypothesized that LPS would trig-
ger hBD2 expression possibly through a CD14-mediated recog-
nition, ultimately resulting in hBD2 induction via activation of
NF-kB. To establish this paradigm, we analyzed the hBD2
mRNA response to LPS in hTBE cells and determined the role
of CD14. Furthermore, we document expression of TLRs in
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these cells and demonstrate activation of NF-kB in response to
LPS.
EXPERIMENTAL PROCEDURES
Reagents—Escherichia coli LPS serotype O127:B8, Igepal CA-630,
nitro blue tetrazolium, and 5-bromo-4-chloro-3-indolylphosphate were
from Sigma. Mouse monoclonal My4 and mouse IgG2b antibodies were
obtained from Beckman Coulter (Miami, FL). IL-1b was from R&D
Systems (Minneapolis, MN).
Primary Culture of hTBE Cells—hTBE cells were isolated under the
auspices of Institutional Review Board approved protocols as described
in detail previously (24). Passage 1 or 2 hTBE cells were cultured at an
air-liquid interface on 24-mm T-COL membrane supports (Costar,
Cambridge, MA) for the number of days indicated in each experiment.
Initial seeding density was 0.7–1 3 106 cells/support. Growth medium
was modified from that in Ref. 24 by the use of bovine pituitary extract
from Upstate Biotechnology, Inc. (Lake Placid, NY) and the elimination
of antibiotics. The medium was periodically tested for endotoxin levels
with the Limulus Amebocyte Lysate assay (BioWhittaker (Walkers-
ville, MD) or Associates of Cape Cod (Falmouth, MA)), and endotoxin
levels were below 100 pg/ml.
LPS and Inflammatory Stimulus—LPS (E. coli) at 5 mg/ml was
added either apically or basolaterally to cultures with 5% human serum
(Sigma catalog no. H4522) as a source of LPS-binding protein. It is
important to note that our cells are normally cultured at an air-liquid
interface and that the cells respond to apical flooding by increased acid
production (yellowing of the media). In preliminary experiments, we
challenged cells with LPS from both sides simultaneously or from only
the basal or apical side (with apical flooding controls). The most con-
sistent response was observed with a basal challenge while maintaining
an air-liquid interface. Since we observed CD14 on both the apical and
basal membrane (this study) and to avoid disturbance of the air-liquid
interface, we chose basal challenge for our studies. IL-1b was added
basolaterally at 25 ng/ml. For blocking experiments, My4 or IgG2b was
added to the cultures both apically and basolaterally 20 min prior to the
addition of LPS.
Northern Blot Analysis—RNA was isolated with TRI-reagent accord-
ing to the manufacturer’s protocol (MRC, Cincinnati, OH). Unless oth-
erwise noted, all of the RNA from one 24-mm T-COL was electrophore-
sed in a single lane on 1.2% agarose-formaldehyde gels. Northern blot
analysis was carried out by standard capillary transfer to a Hybond N
membrane (Amersham Pharmacia Biotech). Blots were hybridized with
Quikhyb (Stratagene, La Jolla, CA) with 2 3 106 counts per ml of
32P-labeled probe. For hBD2, either a random primed fragment (bp11–
265; accession number Z71389) or an end-labeled oligonucleotide (59-A-
ATATGAAGAGGAACGAGAAGAGGAGATACAAGACCCTCAT-39) was
used. Fragments for CD14 (base pairs 52–563, accession number
X06882) and TLR4 (base pairs 446–945, accession number U88880)
were PCR-cloned with the Invitrogen (Carlsbad, CA) TOPO TA or TA
kit, respectively. The inserts were isolated and random prime-labeled
(Rediprime; Amersham Pharmacia Biotech) for use as probes. Inserts
for TLR2 (base pairs 2012–2600; accession number U88878) and g-actin
(XhoI fragment of pHFgA-1 (25) encompassing the entire cDNA se-
quence) also were random primed. All accession numbers refer to Gen-
BankTM. Quantitation was performed with a Molecular Dynamics
PhosphorImager.
IL-8 Production—The production of IL-8 was measured by enzyme-
linked immunosorbent assay (R&D Systems) in samples of the growth
medium taken before and after LPS challenge.
Reverse Transcription (RT)-PCR—RT-PCR was performed as de-
scribed previously (24). Seven-day-old cultures were used for the RNA
isolation. Primers used are listed in Table I. The THP-1 cells were
obtained from the ATCC (TIB 202) and were maintained in RPMI 1640
with 5 3 1025 M 2-mercaptoethanol plus 10% fetal bovine serum. Lung
RNA was obtained from CLONTECH (Palo Alto, CA).
Western Blot and Immunoprecipitation Analysis—For detection of
hBD2, Western blots were performed as in Ref. 18. Briefly, cells were
lysed in 5% acetic acid, and acid-soluble proteins were extracted overnight
at 4 °C. After lyophilization, proteins were separated on acid urea-poly-
acrylamide gels and electroblotted to an Immobilon PSQ membrane (Mil-
lipore Corp., Bedford, MA). Membranes were blocked and incubated with
a 1:1000 dilution of anti-hBD2 (the kind gift of Tomas Ganz, UCLA, Los
Angeles, CA) or normal rabbit serum overnight. Subsequently, blots were
incubated with an alkaline phosphatase-conjugated secondary antibody
(Jackson Immunoresearch, West Grove, PA) and visualized with nitro
blue tetrazolium/5-bromo-4-chloro-3-indolylphosphate.
Cell surface biotinylation, immunoprecipitation, and Western blots
were performed as described (26). Briefly, 7-day-old cultures of hTBE
cells were surface-biotinylated with EZ-Link sulfo-NHS-biotin (Pierce)
according to the manufacturer’s protocol. Proteins were isolated in
radioimmune precipitation buffer and immunoprecipitated with the
My4 antibody or an IgG2b isotype control. Immunoprecipitated pro-
teins were run on a 4–20% acrylamide gel (NOVEX, San Diego, CA) and
electroblotted to a polyvinylidene difluoride membrane. Biotinylated
proteins were detected by streptavidin-linked horseradish peroxidase
and chemiluminescence (Pierce).
Electrophoretic Mobility Shift Assays—Cells were harvested from the
membrane in phosphate-buffered saline plus protease inhibitors (1 mM
phenylmethylsulfonyl fluoride, 1.2 mg/ml leupeptin, 1 mg/ml pepstatin,
0.5 mM EDTA) with a cell scraper. Extracts were prepared according to
the method of Dignam (27) with the modification that Igepal CA-630
(0.25%) was added to buffer A before homogenization, and buffer D was
added directly to the cleared supernatant rather than dialyzed against
buffer D. Complementary oligonucleotides containing the NF-kB con-
sensus sequence from the class I MHC promoter (28) were annealed and
labeled by end filling with Klenow and [32P]dCTP. Binding reactions
were performed according to Ref. 29, and complexes were separated by
5% nondenaturing polyacrylamide gel electrophoresis in Tris-glycine-
EDTA buffer. For competition experiments, 20 mg of NF-kB consensus
or mutant oligonucleotides from Santa Cruz Biotechnology, Inc. (Santa
Cruz, CA) were added to the binding reaction.
RESULTS
Inducibility of antimicrobial factors by bacterial products
and/or inflammatory mediators is a key feature of innate im-
munity. LPS induction of hBD2 gene expression was examined
in passage 1 or 2 hTBE grown in culture at an air-liquid
interface. Cells were grown for 7, 14, or 21 days, which corre-
sponds to distinct stages of mucociliary differentiation (24), and
were treated with E. coli LPS at 1 or 5 mg/ml in the presence of
human serum as a source of LPS-binding protein. Fig. 1 shows
that hBD2 mRNA levels are highest early in culture and that
expression is induced after incubation with LPS. In subsequent
experiments conducted at 7 days postseeding, steady-state lev-
els of hBD2 mRNA increased an average of 3-fold following LPS
(range 1.3–6.3-fold, 10 separate experiments, with seven dif-
ferent patient cell samples) and up to 16-fold following IL-1b
(data not shown), which is consistent with published results
(23, 30).
The LPS dose-response relationship for hBD2 induction in
hTBE cells is shown in Fig. 2A, which is a graphical represen-
tation of the results from a Northern blot with triplicate sam-
ples. An LPS dose of 10 ng/ml, which typically induces strong
responses in monocyte-derived cells, did not alter hBD2 expres-
sion in hTBE cells, but hBD2 mRNA increased following 100
ng/ml to 1 mg/ml of LPS. As shown in Fig. 2B, we examined LPS
stimulation of the proinflammatory cytokine IL-8 in the same
cultures. The basal expression of IL-8 is approximately 10-fold
TABLE I
Gene (accession no.) Forward primer (59 3 39) Bases Reverse primer (59 3 39) Bases
g-Actin (M19283) GCCAACAGAGAGAAGATGAC 1350–1369 AGGAAGGAAGGCTGGAAC 2087–2070
TLR1 (U88540) TGCCCTGCCTATATGCAA 381–398 GAACACATCGCTGACAACT 936–918
TLR2 (U88878) CCTACATTAGCAACAGTGACCTAC 323–346 ATCTCGCAGTTCCAAACATTCCA 822–800
TLR3 (U88879) CGCCAACTTCACAAGGTA 277–294 GGAAGCCAAGCAAAGGAA 966–949
TLR4 (U88880) AGATGGGGCATATCAGAGC 446–464 CCAGAACCAAACGATGGAC 945–927
TLR5 (U88881) TTCTGACTGCATTAAGGGGAC 93–113 TTGAGCAAAGCATTCTGCAC 660–641
TLR6 (AB020807) CCTCAACCACATAGAAACGAC 832–852 CACCACTATACTCTCAACCCAA 1363–1342
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higher in the presence of serum than in cultures with media
alone (data not shown). However, $1 mg/ml LPS induced a
significant increase over this elevated base line.
The time course of hBD2 mRNA induction is shown in Fig.
3A. LPS increased hBD2 mRNA at 12 and 24 h, but not 6 h,
following challenge. Basal hBD2 expression declined over 24 h,
possibly in response to the serum added to the medium as a
source of LPS-binding protein. Subsequent analyses were per-
formed 24 h following LPS addition. Fig. 3B demonstrates a
corresponding LPS-induced increase in hBD2 protein as de-
tected by Western blot.
The GPI-linked cell surface protein, CD14, is known to par-
ticipate in LPS responsiveness in bovine tracheal epithelial
cells (14). We examined hTBE cells for the expression and
production of CD14, as well as its involvement in the up-
regulation of hBD2. Immunoprecipitation of biotinylated sur-
face proteins reveals that membrane-bound CD14 is found on
both the apical and basolateral surfaces of hTBE cells (Fig. 4A).
The Northern blot shown in Fig. 4B indicates that mRNA for
CD14 is present in hTBE cells, and the levels of CD14 are not
altered in response to LPS. To test the role of CD14 in the
stimulation of hBD2 gene expression, we challenged cultures
with LPS in the presence of either My4, a neutralizing mono-
clonal antibody to CD14, or an IgG2b isotype control. The
Northern blot in Fig. 4B and the corresponding graphical rep-
resentation in Fig. 4C are representative of three experiments
and show that My4 blocks the up-regulation of hBD2 by LPS.
Thus, CD14, either membrane-bound or the soluble form, is
necessary for the LPS-induced increase in hBD2 mRNA.
As a GPI-linked protein without a cytoplasmic domain, CD14
cannot act alone as a classical signal transduction molecule. As
noted above, recent studies suggest that CD14-TLR complexes
may function to initiate a signal transduction event. We exam-
ined hTBE cells for the expression of TLR genes by RT-PCR
(Fig. 5A). Our results show that mRNA for all six published
hTLRs is expressed in these cultures. Based on published re-
sults (10, 11, 31) TLRs 2 and 4 are probable LPS-signaling
intermediates. Northern blot analysis shown in Fig. 5B indi-
cates that hTLR2 is abundantly expressed in hTBE cells and
that there is no induction by LPS. Human TLR4 expression is
also detectable by Northern blot but is much less abundant
than TLR2 and is also not regulated by LPS (Fig. 5C).
The promoter region of the hBD2 gene has three NF-kB
consensus binding sites, suggesting a role for this family of
transcription factors as a mechanism for gene regulation. Us-
ing electrophoretic mobility shift assays, we determined
whether LPS-induced hBD2 expression was associated with
activation of NF-kB. Upon induction with LPS for varying time
periods, we isolated nuclear extracts from hTBE cells. THP-1
cells were used as a positive control (32). Fig. 6A indicates that
NF-kB is activated after a 1-h incubation with LPS in hTBE
cells and persists through 8 h. A stronger and more persistent
shift is seen in response to IL-1b. Preincubation of the extracts
with unlabeled NF-kB consensus oligonucleotide, but not with
unlabeled mutant oligonucleotide, effectively competes for
binding to the labeled oligonucleotide demonstrating specificity
(Fig. 6B).
DISCUSSION
The airway epithelium comprises an important barrier
against invasion by airborne pathogens. We show that epithe-
lial cells lining the respiratory tract induce the host defense
gene hBD2 at both the mRNA and protein level in response to
LPS, a pathogen-associated pattern molecule. Human b-defen-
sin-2 mRNA also is increased by IL-1b (23, 30), suggesting that
a similar protective effect accompanies inflammation even
when not directly induced by bacterial products. High levels of
b-defensin gene expression have been observed at sites of in-
flammation in the bovine tongue (33) and airway (34). There
are several examples of b-defensin induction in response to
infection and inflammation by human tissues that provide
barrier functions, including the oral mucosa (30, 35), occular
epithelium (36), and intestinal epithelium (37). Together these
data suggest that a peptide-based antimicrobial host response
during infection and inflammation is intrinsic to mucosal
surfaces.
The molecular pathway for the induction of antimicrobial
peptides in the airway is both similar to and different from
circulating professional phagocytes, such as monocytes. While
initially discovered and extensively studied in myeloid-derived
cells, CD14 is also expressed by bovine and murine epithelial
cells (14, 38). Our results demonstrate both CD14 mRNA and
cell surface protein in human airway epithelial cells. We found
that CD14 mRNA was not increased in response to LPS,
whereas it is in monocytes (39). The CD14-specific antibody,
My4, inhibited LPS-induced hBD2 expression in hTBE cells,
which suggests a critical role for CD14 in the mechanism by
which airway epithelial cells recognize and respond to bacterial
products.
Induction of hBD2 or IL-8 in hTBE requires relatively high
concentrations (1–5 mg/ml) of LPS, whereas phagocytic cells or
bovine epithelial cells are activated by 10–20 ng/ml concentra-
tions. Thus, while CD14 is an important mediator of LPS
responsiveness in hTBE cells, initiation and coupling to down-
stream signal transduction events appears to be much less
efficient than in monocyte-derived cells. Primary cultures of
bovine tracheal epithelial cells respond to lower levels of LPS
FIG. 1. Induction of hBD2 mRNA in hTBE cells by LPS. North-
ern blot analysis of mRNA from hTBE cells grown for 7, 14, or 21 days.
Cells were induced with LPS (1 or 5 mg/ml), and RNA was harvested
24 h later. The blot was hybridized with a probe for hBD2, and the
ethidium bromide-stained 18 S rRNA band is shown as a loading
control.
FIG. 2. Steady state hBD2 mRNA and production of IL-8 by
hTBE cells in response to LPS. A, cells were cultured for 7 days and
exposed to varying amounts of E. coli LPS. RNA was harvested 24 h
later, and the resulting Northern blot was hybridized with probes for
hBD2 and subsequently for g-actin. The hBD2 signal was normalized to
g-actin and is presented in arbitrary units (A.U.). B, enzyme-linked
immunosorbent assay measurements of IL-8 protein in the basolateral
medium after treatment of cells with LPS as described above. In both A
and B, the overall LPS effect is significant by analysis of variance (p ,
0.001 for hBD2; p 5 0.007 for IL-8). Both the 1- and 5-mg doses are
significantly different from no LPS by the Tukey test for multiple
comparisons (p 5 0.002 and 0.003 for hBD2 and p 5 0.007 and p 5 0.015
for IL-8, respectively). Values are the mean 6 S.E. of triplicate samples.
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than passaged hTBE cells.2 Surface CD14 in passage 1 hTBE
cells was detected by immunoprecipitation, but expression was
much less than in the vitamin D3-differentiated HL60 cells
used as a positive control. Further studies are necessary to
determine CD14 protein levels in normal and diseased human
airways in vivo.
The low sensitivity of the hTBE cells to LPS could be due to
desensitization during culture. The medium for hTBE cells
contains several biologicals including albumin, EGF, trans-
ferrin, and bovine pituitary extract. The practical limit of en-
dotoxin reduction was 100 pg/ml. Thus, desensitization by ba-
sal endotoxin levels in the medium could have contributed to
the apparent resistance of hTBE cells to LPS. However, poly-
myxin B addition did not reduce basal levels of IL-8 production
(data not shown). As demonstrated by others, LPS desensitiza-
tion of monocytic cell lines and murine macrophages appears to
require 20–100 ng of LPS/ml (40–42). In LPS-tolerant cells,
DNA binding activity in NF-kB gel shift assays consists mostly
of p50 homodimers in LPS-tolerant cells (40, 41). The NF-kB
gel shift assays in our studies are consistent with those seen in
LPS-sensitive Mono Mac 6 cells, where the low mobility upper
band representing the p50/p65 heterodimer is more prominent.
We hypothesize that the low LPS responsiveness of hTBE cells
reflects the low level of CD14 expression compared with mono-
cytic cells. In support of this hypothesis are the findings that
the response to LPS in THP-1 cells correlates inversely with
the level of CD14 expression (43).
The lack of a cytoplasmic domain in GPI-anchored CD14
implies that it acts in concert with other proteins to transduce
signals. Several lines of evidence suggest that TLRs contribute2 G. Diamond, unpublished observations.
FIG. 3. LPS induction of hBD2 mRNA and protein. A, hTBE cells cultured for 7 days were treated with LPS (5 mg/ml) for 6, 12, or 24 h. RNA
was isolated, and the resulting Northern blot was hybridized to hBD2 and g-actin probes. Open boxes are the mean of duplicate samples, and the
hatched boxes are the mean 6 S.E. of triplicate values. Although LPS induction of hBD2 was relatively low in this experiment, the 24-h time point
was significantly greater than control when compared by Student’s t test with Bonferroni’s multiple comparison correction. p values for 6, 12, and
24 h were 0.44, 0.08, and 0.01, respectively. B, acid urea-polyacrylamide gel electrophoresis Western blot analysis of hBD2 in acid-soluble proteins
from hTBE cells. Lanes 1–3 represent 10, 3, and 1 ng of hBD2 standard. Proteins in lanes 4–7 were isolated from a single 24-mm hTBE culture
exposed for 24 h to medium alone, medium plus serum, medium plus serum and LPS, or medium with IL-1b, respectively. No bands were visible
on a duplicate blot treated with normal rabbit serum (not shown). A.U., arbitrary units.
FIG. 4. The role of CD14 in the LPS-mediated induction of
hBD2 gene expression. A, biotinylated surface proteins were immu-
noprecipitated with the My4 antibody specific to CD14 or an IgG2b
isotype control. Electrophoresed immunoprecipitated proteins were
blotted and then visualized by streptavidin-conjugated horseradish per-
oxidase and chemiluminescent detection. As a positive control, HL60
cells, a myeloid cell line, were differentiated with 50 nM vitamin D. B,
My4, a neutralizing antibody to CD14, was added to 7-day-old hTBE
cultures at 5 mg/ml both apically and basolaterally for 20 min prior to
24-h basolateral LPS stimulation. IgG2b was used as an isotype control.
RNA was isolated from the cultures, and the resulting Northern blot
was hybridized sequentially with probes for hBD2, CD14, and g-actin.
The blot shown is representative of three experiments. C, a graphical
representation of the blot in B. hBD2 signals were standardized to
g-actin and are presented in arbitrary units. When analyzed by analysis
of variance, there was a very significant overall treatment effect (p ,
0.001). My4 abolished LPS induction of hBD2 mRNA, (p , 0.001 for
LPS alone versus My4 plus LPS according to the Tukey test for multiple
comparisons). The antibody control for My4 (IgG2b plus LPS) is signif-
icantly greater than its own control (IgG2b alone), p , 0.05. A.U.,
arbitrary units.
FIG. 5. Expression of Toll-like receptors on hTBE cells. A, RT-
PCR analysis of hTLR1–6 with total mRNA from hTBE cells. The
absence of genomic DNA was verified by an intron-spanning primer
pair from the g-actin gene. All bands are of the predicted size. RNA
isolated from 7-day-old hTBE cultures with and without LPS induction
was blotted and hybridized with either hTLR2 (B) or hTLR4 (C) and
subsequently with g-actin probes.
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transmembrane signaling functions. Recent reports indicate
that TLR2 mediates both LPS sensitivity (44) and responsive-
ness to Gram-positive bacteria (45) in transfected 293 cells.
However, TLR2 null hamster macrophages still respond to LPS
(46), suggesting a complementary function for other TLRs in-
cluding TLR4. It is now known that mouse TLR4 is equivalent
to the mouse LPS gene conferring LPS sensitivity (12). Using
RT-PCR, we demonstrate mRNA for the six published hTLR
sequences in hTBE cells and have established that hTLR2 and
-4 are present at levels detectable by Northern blot of whole
RNA. Further studies are needed to clearly elucidate the spe-
cific roles of TLR2 and/or -4 in initiating signal transduction
responses in the airway. This will require the development of
tools including neutralizing antibodies analogous to My4, suc-
cessful strategies to generate dominant negative phenotypes in
difficult to transfect polarized hTBE cells, and genetically en-
gineered animals.
Studies of the Drosophila Toll pathway for antimicrobial factor
induction and the discovery of inducible antimicrobial peptide
expression in mammals suggest an evolutionarily conserved ac-
tivation pathway. MUC2 mucin, which can be considered an
innate immune molecule, increases in response to Psuedomonas
aeruginosa through NF-kB activation (47). We demonstrate that
hTBE cells activate the NF-kB pathway in response to LPS
similarly to bovine epithelial cells (16). Interestingly, hTBE acti-
vation of NF-kB is of a lower magnitude and more transient
following LPS compared with IL-1b, which is consistent with the
typically lower -fold induction of hBD2 mRNA that we observed.
It will be interesting to compare and contrast the function of
components in the IL-1b and LPS signal transduction pathways
to discover the basis for this difference.
In summary, the human airway epithelium responds to prod-
ucts from infectious microorganisms by inducing antimicrobial
peptides. The activation pathway shares elements with cells of
the myeloid lineage in that the epithelium expresses pathogen-
associated recognition receptors. These receptors identify and
transduce a signal ultimately activating NF-kB, which in turn
up-regulates antimicrobial peptide genes. Taken together with
studies in other organ systems, this innate immune mechanism
is probably intrinsic to most if not all epithelia, providing a
barrier function. Although in vitro studies such as ours intro-
duce a level of uncertainty, it appears that hTBE cells require
much higher doses of LPS than blood monocytes. This is per-
haps not surprising in view of the potential for very high LPS
aerosol exposure in certain environments (48). It will be impor-
tant to determine the mechanisms, possibly involving CD14
and hTLRs, by which the organism balances defense against
inhaled microbes with the potential pathophysiology inherent
to chronic airway inflammation.
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